Artificial intelligence based precision medical unicorn company: Tempus Labs, Inc

Tempus Labs, Inc., founded in 2015 and headquartered in Chicago, Illinois, USA, is a artificial intelligence The practical application in the field of medical care is a technology company that promotes precision medicine.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/tempus.html

Tempus Labs, Inc

Tempus Labs, Inc. is a technology company focusing on biotechnology and health care, aiming to improve cancer treatment and clinical practice by using a data-driven approach. Tempus Labs has one of the largest clinical and molecular data libraries in the world, as well as an operating system that makes these data easy to access and use. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/tempus.html

Tempus Labs is committed to collecting, integrating and analyzing large-scale clinical and molecular data to help doctors and researchers better understand cancer and other diseases, and provide personalized treatment programs for patients. The company has accelerated the progress of medical research and clinical practice by using advanced technologies such as artificial intelligence, machine learning and genomics. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/tempus.html

Tempus Labs' mission is to provide more accurate and effective medical care for patients through innovative technologies and data-driven methods. They cooperate with medical institutions, academic research institutions and pharmaceutical companies to jointly promote the development of medical science, strive to improve clinical practice, and provide patients with better treatment options. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/tempus.html

Tempus Labs, Inc. technology includes: The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/tempus.html

1. Data collection and consolidation : Tempus uses advanced data collection technology to obtain clinical and molecular data from multiple sources, including patient genome data, clinical records, imaging data, etc. These data are the basis of the company's research and analysis, helping doctors and researchers better understand the conditions of diseases and patients.
2. Data analysis and mining : Tempus uses artificial intelligence, machine learning, big data analysis and other technologies to conduct in-depth analysis and mining of the collected data. Through the processing and interpretation of large-scale data, Tempus can find patterns, trends and correlations of diseases and provide scientific basis for personalized medicine.
3. Genomics and Bioinformatics : Tempus is committed to studying innovative technologies in genomics and bioinformatics, including genome sequencing, gene expression analysis, proteomics, etc. These technologies can help to understand the molecular mechanism of diseases, find therapeutic targets, and develop personalized therapeutic schemes.
4. Medical data platform : Tempus has established a medical data platform to integrate clinical and molecular data and provide them to doctors, researchers, pharmaceutical companies and other partners. This platform provides important tools and resources for medical research, clinical practice and drug research and development, and promotes the innovation and progress of the medical industry.

Tempus Labs, Inc. Financing Encyclopedia

In April 2017, Tempus Labs, Inc. completed a round B financing of $30 million. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/tempus.html

In September 2017, Tempus Labs, Inc. completed New Enterprise Associates And the $70 million round C financing led by Revolution, and the investment of Revolution Growth. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/tempus.html

In March 2018, Tempus Labs, Inc. completed T. Rowe Price Round D financing of 80 million US dollars led by investors, New Enterprise Associates , Revolution and Revolution Growth. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/tempus.html

In August 2018, Tempus Labs, Inc. completed Baillie Gifford The $110 million round E financing led by T Rowe Price、 New Enterprise Associates , Revolution and Revolution Growth. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/tempus.html

In May 2019, Tempus Labs, Inc. completed the US $200 million round F financing led by Baillie Gifford, and Novo Holdings, New Enterprise Associates, Revolution, Revolution Growth, etc. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/tempus.html

In March 2020, Tempus Labs, Inc. completed the round G financing of $100 million. Baillie Gifford, Novo Holdings, New Enterprise Associates, T Rowe Price and Franklin Templeton Co investment.

In December 2020, Tempus Labs, Inc. received $250 million in debt financing funds, including Baillie Gifford, Novo Holdings, Franklin Templeton and Google Co investment.

In December 2020, Tempus Labs, Inc. completed Google The $200 million round of G+financing led by T Rowe Price, Baillie Gifford, Novo Holdings, Franklin Templeton, etc.

In October 2022, Tempus Labs, Inc. received $175 million in debt financing funds, Ares Management Exclusive investment.

In October 2022, Tempus Labs, Inc. received $100 million in venture capital.

Tempus Labs, Inc. US equity investment

Unlisted company ， Company official website , waiting for Tempus Labs, Inc IPO Listing.